Cargando…
Metformin maintains intrahepatic triglyceride content through increased hepatic de novo lipogenesis
OBJECTIVE: Metformin is a first-line pharmacotherapy in the treatment of type 2 diabetes, a condition closely associated with non-alcoholic fatty liver disease (NAFLD). Although metformin promotes weight loss and improves insulin sensitivity, its effect on intrahepatic triglyceride (IHTG) remains un...
Autores principales: | Green, Charlotte J, Marjot, Thomas, Walsby-Tickle, John, Charlton, Catriona, Cornfield, Thomas, Westcott, Felix, Pinnick, Katherine E, Moolla, Ahmad, Hazlehurst, Jonathan M, McCullagh, James, Tomlinson, Jeremy W, Hodson, Leanne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859923/ https://www.ncbi.nlm.nih.gov/pubmed/35038311 http://dx.doi.org/10.1530/EJE-21-0850 |
Ejemplares similares
-
Sex Differences in Hepatic De Novo Lipogenesis with Acute Fructose Feeding
por: Low, Wee Suan, et al.
Publicado: (2018) -
Acute intermittent hypoxia drives hepatic de novo lipogenesis in humans and rodents
por: Hazlehurst, Jonathan M., et al.
Publicado: (2022) -
Sodium‐glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulin‐resistant patients without type 2 diabetes
por: Marjot, Thomas, et al.
Publicado: (2019) -
Using total plasma triacylglycerol to assess hepatic de novo lipogenesis as an alternative to VLDL triacylglycerol
por: Hodson, Leanne, et al.
Publicado: (2020) -
Hepatic de novo lipogenesis is suppressed and fat oxidation is increased by omega-3 fatty acids at the expense of glucose metabolism
por: Green, Charlotte J, et al.
Publicado: (2020)